Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ADC Therapeutics Q3 Adj. EPS $(0.19) Beats $(0.36) Estimate, Sales $16.427M Miss $17.077M Estimate

Author: Benzinga Newsdesk | November 10, 2025 07:32am
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.51 percent. This is a 32.14 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $16.427 million which missed the analyst consensus estimate of $17.077 million by 3.81 percent. This is a 11.03 percent decrease over sales of $18.464 million the same period last year.

Posted In: ADCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist